Moleculin Biotech, Inc. (MBRX) is a publicly traded Healthcare sector company. As of May 21, 2026, MBRX trades at $2.47 with a market cap of $11.15M and a P/E ratio of -0.08. MBRX moved +0.00% today. Year to date, MBRX is -40.00%; over the trailing twelve months it is -90.45%. Its 52-week range spans $1.79 to $91.25. Analyst consensus is strong buy with an average price target of $21.00. Rallies surfaces MBRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for MBRX combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $2.47 |
| Market Cap | $11.15M |
| P/E Ratio | -0.08 |
| EPS | $-28.42 |
| Dividend Yield | 0.00% |
| 52-Week High | $91.25 |
| 52-Week Low | $1.79 |
| Volume | 218 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-33.56M |
| Gross Margin | 0.00% |
3 analysts cover MBRX: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $21.00.